Journal
JOURNAL OF RHEUMATOLOGY
Volume 44, Issue 10, Pages 1522-1528Publisher
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.160904
Keywords
PSORIATIC ARTHRITIS; CORE SET; OUTCOME MEASURES
Categories
Funding
- Scientist Development Award from the Rheumatology Research Foundation
- Johns Hopkins Arthritis Center Discovery Fund
- US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [K23 AR063764]
- (RDRCC Human Subjects Research Core) from NIAMS [P30-AR053503]
- Camille J. Morgan Arthritis Research and Education Fund
- Celgene
- Janssen
- AbbVie
- Pfizer
- National Institute for Health Research [RP-PG-1212-20007]
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
- OMERACT
- National Institute for Health Research [CL-2011-02-001, RP-PG-1212-20007] Funding Source: researchfish
Ask authors/readers for more resources
Objective. To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS). Methods. At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants. Results. We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient's global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda. Conclusion. The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available